1. Home
  2. ZKIN vs RNTX Comparison

ZKIN vs RNTX Comparison

Compare ZKIN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZK International Group Co. Ltd

ZKIN

ZK International Group Co. Ltd

N/A

Current Price

$1.40

Market Cap

28.5M

Sector

Industrials

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKIN
RNTX
Founded
2015
2001
Country
China
United States
Employees
N/A
11
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5M
30.0M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ZKIN
RNTX
Price
$1.40
$1.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
6.2K
80.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.02
52 Week High
$4.47
$2.22

Technical Indicators

Market Signals
Indicator
ZKIN
RNTX
Relative Strength Index (RSI) 48.01 49.01
Support Level $1.31 $1.06
Resistance Level $2.10 $1.30
Average True Range (ATR) 0.15 0.11
MACD 0.01 0.01
Stochastic Oscillator 58.95 46.15

Price Performance

Historical Comparison
ZKIN
RNTX

About ZKIN ZK International Group Co. Ltd

ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: